

News Release

Innovotech Reports Nine Months Ending September 30, 2017 Financial Results

Edmonton, Alberta, November 03, 2017 – Innovotech Inc. (TSX-V: IOT), an innovator in the field of biofilm product development, today announced its unaudited financial and operational results for the nine months ended September 30, 2017.

Highlights:

- Revenue for nine-month period up 20% from previous year
- Debt settlement improves financial position
- US patent issued for silver antimicrobial compound

“We continue to have encouraging operating results. New financing received in the second quarter combined with the AAFC (Agriculture and Agri-Food Canada) debt settlement improves our financial position. It frees us to focus on the business. We continue to build and diversify our contract research business and continue our efforts to commercialize our proprietary products.” said Chief Operating Officer Dr. Amin Omar.

Summary of Quarterly Results

	2017			2016			2015	
(\$)	Q3	Q2	Q1	Q4	Q3	Q2	Q1	Q4
Gross revenue	258,500	208,696	328,060	342,291	257,580	206,387	199,340	163,248
R&D expense	11,575	12,132	7,254	7,568	12,658	83,098	45,260	31,081
Net income (loss)	684,316	(26,356)	66,136	(130,468)	29,420	(68,843)	(45,644)	(50,073)
Net income (loss) per share	0.02	0.00	0.00	0.00	0.00	(0.00)	(0.00)	(0.00)

Financial Summary (EBITDAS)

This non-GAAP measure is not defined under IFRS and may not be comparable to similar measures presented by other companies. For the Company, it is defined as earnings before interest, taxes, dividends, amortization and depreciation, and stock based compensation (EBITDAS). Management believes that EBITDAS as defined here is useful in providing investors with additional information to assist them in understanding the operational performance.

	2017			2016			2015	
(\$)	Q3	Q2	Q1	Q4	Q3	Q2	Q1	Q4
Net income (loss)	684,316	(26,356)	66,136	(137,468)	36,420	(68,843)	(45,644)	(50,073)
Net interest expense	4,910	10,339	10,857	261,238	16,763	17,522	20,365	19,215
Depreciation and Amortization	4,304	4,204	4,051	859	6,193	6,194	6,194	10,580
Stock based compensation	-	-	-	-	-	-	-	-
EBITDAS	693,530	81,044	124,629	59,376	(45,127)	(19,085)	(20,278)	(17,704)

For more information contact:

Dr. James Timourian, President
Innovotech Inc.

Connect with us:
Website: www.innovotech.ca

Email: james.timourian@innovotech.ca
Telephone: 780.448.0585

This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company's reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company's exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.